This medication is taken by injection.
Kesimpta® is a monoclonal antibody that binds to a docking site (CD20) on some immune B cells and depletes them. B cells are among immune cells that have been implicated in causing nervous system damage in MS. Kesimpta is approved by the FDA for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease, in adults.
Read the Society's news bulletin on the FDA approval of ofatumumab here
to see the prescribing information for healthcare professionals.
to see the medication guide for patients.
Financial Assistance Program
Check back for information when it becomes available.